Literature DB >> 30664524

Comparison of pre-oxygenation using spontaneous breathing through face mask and high-flow nasal oxygen: A randomised controlled crossover study in healthy volunteers.

Jean-Luc Hanouz1, David Lhermitte, Jean-Louis Gérard, Marc Olivier Fischer.   

Abstract

BACKGROUND: High-flow nasal oxygen (HFNO) therapy has been proposed for pre-oxygenation before intubation, but the end-tidal fraction of oxygen (ETO2) obtained remains unknown. OBJECTIVE(S): To compare the ETO2 following a 3 min pre-oxygenation with HFNO and face mask.
SETTING: Operating room in a primary university hospital.
DESIGN: A randomised crossover study. PARTICIPANTS: Fifty healthy volunteers.
INTERVENTIONS: Participants were randomly pre-oxygenated through spontaneous breathing 100% oxygen in a face mask and with HFNO (mouth closed, heated and humidified gas flow at 60 l min). In the face mask group, the ETO2 was measured continuously. In the HFNO group, the nasal cannula was quickly exchanged with a face mask while the subject held their breath at end inspiration and the ETO2 was measured after a deep expiration. The protocol ended when ETO2 reached 90% or otherwise at 6 min. MAIN OUTCOME MEASURES: The primary endpoint was the ETO2 after 3 min of pre-oxygenation. Secondary endpoints were the proportion of participants with an ETO2 at least 90% and the time until the ETO2 at least 90%.
RESULTS: The ETO2 after 3 min of pre-oxygenation was 89 (2) % and 77 (12) % in the face mask and HFNO groups [difference 12% (95% confidence interval, 95% CI: 8 to 15]; P < 0.001), respectively. After 3 min of pre-oxygenation, 54 and 4% (P < 0.001) of volunteers had an ETO2 at least 90% in the face-mask and HFNO groups, respectively. After 6 min of pre-oxygenation, 96 and 46% (P < 0.001) of volunteers had an ETO2 at least 90% in the face-mask and HFNO groups, respectively. In the face mask group, the hazard ratio to achieve an ETO2 of 90% was 5.3 (95% CI: 3.2 to 8.9; P < 0.001).
CONCLUSION: Our study demonstrates that pre-oxygenation with HFNO is not a reliable method of pre-oxygenation before the induction of anaesthesia. TRIAL REGISTRATION: clinical trial NCT03399695.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30664524     DOI: 10.1097/EJA.0000000000000954

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  6 in total

1.  Nasal high-flow preoxygenation for endotracheal intubation in the critically ill patient? Con.

Authors:  Jean-Luc Hanouz; Jean Louis Gérard; Marc Olivier Fischer
Journal:  Intensive Care Med       Date:  2019-02-12       Impact factor: 17.440

2.  Avoiding desaturation during endotracheal intubation: is high-flow nasal cannula the answer?

Authors:  Thais Dias Midega; Guilherme Benfatti Olivato; Fabio Barlem Hohmann; Ary Serpa Neto
Journal:  Ann Transl Med       Date:  2019-09

3.  Clinical efficacy of high-flow nasal humidified oxygen therapy in patients with hypoxemia.

Authors:  Qiliang Hou; Zhigang Zhang; Ting Lei; Maozhou Gan; Xiangjun Wu; Weigang Yue; Bin Li; Lin Deng; Hongchang Gong
Journal:  PLoS One       Date:  2019-06-06       Impact factor: 3.240

4.  Comparison of the effectiveness of high-flow nasal oxygen vs. standard facemask oxygenation for pre- and apneic oxygenation during anesthesia induction: a systematic review and meta-analysis.

Authors:  Jian-Li Song; Yan Sun; Yu-Bo Shi; Xiao-Ying Liu; Zhen-Bo Su
Journal:  BMC Anesthesiol       Date:  2022-04-06       Impact factor: 2.217

5.  A comparison of high-flow nasal cannula and standard facemask as pre-oxygenation technique for general anesthesia: A PRISMA-compliant systemic review and meta-analysis.

Authors:  Hsien-Cheng Kuo; Wan-Chi Liu; Chun-Cheng Li; Yih-Giun Cherng; Jui-Tai Chen; Hsiang-Ling Wu; Ying-Hsuan Tai
Journal:  Medicine (Baltimore)       Date:  2022-03-11       Impact factor: 1.817

6.  Atelectasis after pre-oxygenation with high-flow nasal cannula oxygen confirmed by electrical impedance tomography.

Authors:  Hansheng Liang; Liang Sun; Yi Feng
Journal:  Indian J Anaesth       Date:  2022-02-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.